Vbi Vaccines Inc buy melinda
Start price
10.08.18
/
50%
?1.81
Target price
01.10.18
€2.62
Performance (%)
24.38%
End price
01.10.18
€2.26
Summary
This prediction ended on 01.10.18 with a price of €2.26. The prediction had a final performance of 24.38%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vbi Vaccines Inc | - | - | - | - |
| iShares Core DAX® | 2,99 % | 3,22 % | 4,27 % | 53,70 % |
| iShares Nasdaq 100 | -1,58 % | -3,17 % | 24,75 % | 76,70 % |
| iShares Nikkei 225® | -2,25 % | -9,92 % | 43,52 % | 60,79 % |
| iShares S&P 500 | -0,01 % | 1,64 % | 20,97 % | 62,81 % |
Comments by melinda for this prediction
In the thread Vbi Vaccines Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology.
Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine.
The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Nombre d'employés : 103 personnes.